个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Guideline on treating Community-acquired pneumonia with Chinese Patent Medicines

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wang Minghang[1,2] * ; Liu Huiguo[3] ; Chen Yaolong[4,5] ; Yu Jiajie[6,7] ; Lin Jiangtao[8] ; Sun Zengtao[9] ; Li Jiansheng[2] ; Bai Gang[10] ; Wen Fuqiang[6,7] ; Xie Yang[1,2] ; Wang Jianxin[11] ; Yang Jiang[2] ; Li Suyun[1,2] ;
单位： [1]The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450046, China [2]Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan province & Education Ministry of P.R. China, Zhengzhou 450000, China [3]Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China [4]China Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730030, China [5]Chinese GRADE Center, Lanzhou, China [6]Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610000, China [7]The Chinese Cochrane Center, Chengdu, China [8]China-Japan Friendship Hospital, Beijing, China [9]The Second Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin, China [10]Nankai University, Tianjin 300193, China [11]Standardization Project Management Office of China Association of Traditional Chinese Medicine, Beijing 100061, China
出处：
DOI： 10.1016/j.phrs.2023.106919
ISSN：

关键词： Community-acquired pneumonia Chinese patent medicines Clinical practice guideline GRADE

摘要：
Community-acquired pneumonia (CAP) is one of the most common infectious diseases, and its morbidity and mortality increase with age. Resistance and mutations development make the use of anti-infective therapy challenging. Chinese patent medicines (CPMs) are often used to treat CAP in China and well tolerable. However, currently there are no evidence-based guideline for the treatment of CAP with CPMs, and the misuse of CPMs is common. Therefore, we established a guideline panel to develop this guideline. We identified six clinical questions through two rounds of survey, and we then systematically searched relevant evidence and performed meta-analyses, evidence summaries and GRADE decision tables to draft recommendations, which were then voted on by a consensus panel using the Delphi method. Finally, we developed ten recommendations based on evidence synthesis and expert consensus. For the treatment of severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Xuebijing injection, Shenfu injection, and Shenmai injection respectively. For the treatment of non-severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Lianhua Qingwen capsule/granule, Qingfei Xiaoyan Pill and Shufeng Jiedu capsule respectively. CPMs have great potential to help in the fight against CAP worldwide, but more high-quality studies are still needed to strengthen the evidence.Copyright © 2023. Published by Elsevier Ltd.

基金：
This work was supported by the Project of Clinical Guideline on CPMs for Dominant Diseases of National Administration of Traditional Chinese Medicine (grant number SATCM-2015-BZ402-047); National NaturalScience Foundation of China (grant number 81873278); and Traditional Chinese Medicine Discipline Construction Project of Henan Province (grant number STGZYXKY-2020001).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 药学
最新[2025]版：
大类 | 2 区 医学
小类 | 1 区 药学
JCR分区：
出版当年[2021]版：
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450046, China [2]Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan province & Education Ministry of P.R. China, Zhengzhou 450000, China
推荐引用方式(GB/T 7714)：
Wang Minghang,Liu Huiguo,Chen Yaolong,et al.Guideline on treating Community-acquired pneumonia with Chinese Patent Medicines[J].PHARMACOLOGICAL RESEARCH.2023,196:doi:10.1016/j.phrs.2023.106919.
APA：
Wang Minghang,Liu Huiguo,Chen Yaolong,Yu Jiajie,Lin Jiangtao...&Li Suyun.(2023).Guideline on treating Community-acquired pneumonia with Chinese Patent Medicines.PHARMACOLOGICAL RESEARCH,196,
MLA：
Wang Minghang,et al."Guideline on treating Community-acquired pneumonia with Chinese Patent Medicines".PHARMACOLOGICAL RESEARCH 196.(2023)

相关文献

[1]Dual-Sampling Attention Network for Diagnosis of COVID-19 From Community Acquired Pneumonia [2]Lower long-term mortality in obese patients with community-acquired pneumonia: possible role of CRP [3]Evaluation of Blood Markers at Admission for Predicting Community Acquired Pneumonia in Chronic Obstructive Pulmonary Disease [4]常用生物标志物及致病菌在社区获得性肺炎病情评估中的作用 [5]Large-scale screening of COVID-19 from community acquired pneumonia using infection size-aware classification. [6]Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: a multicentre prospective study [7]Large-scale screening to distinguish between COVID-19 and community-acquired pneumonia using infection size-aware classification [8]Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition) [9]Activation and Functional Alteration of Mucosal-Associated Invariant T Cells in Adult Patients With Community-Acquired Pneumonia [10]Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis.

资源点击量：428 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）